Clinical Trial Update: Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating HLX26 in combination with serplulimab for metastatic colorectal cancer has been terminated. No efficacy or safety results are provided …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• HLX26 (anti-LAG-3 monoclonal antibody)
• Serplulimab (serplulimab)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Colorectal Cancer Metastatic | Phase 2 | Status: TERMINATED